23,897 Shares in Agilent Technologies, Inc. $A Bought by ABN Amro Investment Solutions

ABN Amro Investment Solutions bought a new stake in Agilent Technologies, Inc. (NYSE:A) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 23,897 shares of the medical research company’s stock, valued at approximately $2,820,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Candriam S.C.A. grew its holdings in shares of Agilent Technologies by 2.4% in the 2nd quarter. Candriam S.C.A. now owns 533,466 shares of the medical research company’s stock valued at $62,957,000 after acquiring an additional 12,510 shares in the last quarter. Impax Asset Management Group plc raised its holdings in Agilent Technologies by 3.1% during the second quarter. Impax Asset Management Group plc now owns 3,022,842 shares of the medical research company’s stock worth $356,726,000 after acquiring an additional 91,048 shares in the last quarter. Police & Firemen s Retirement System of New Jersey boosted its position in Agilent Technologies by 3.0% during the second quarter. Police & Firemen s Retirement System of New Jersey now owns 43,058 shares of the medical research company’s stock valued at $5,081,000 after purchasing an additional 1,268 shares during the last quarter. Bailard Inc. grew its stake in Agilent Technologies by 14.3% in the second quarter. Bailard Inc. now owns 3,007 shares of the medical research company’s stock valued at $355,000 after purchasing an additional 376 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in Agilent Technologies by 1.6% in the second quarter. Geode Capital Management LLC now owns 7,319,530 shares of the medical research company’s stock valued at $860,137,000 after purchasing an additional 115,183 shares in the last quarter. 87.41% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. Wall Street Zen raised Agilent Technologies from a “hold” rating to a “buy” rating in a report on Friday, October 3rd. Evercore ISI upped their price target on shares of Agilent Technologies from $128.00 to $140.00 and gave the stock an “in-line” rating in a research report on Tuesday, October 7th. UBS Group upgraded shares of Agilent Technologies from a “neutral” rating to a “buy” rating and increased their price target for the company from $130.00 to $170.00 in a research note on Wednesday, October 8th. Rothschild & Co Redburn assumed coverage on shares of Agilent Technologies in a research note on Wednesday, October 8th. They set a “buy” rating and a $165.00 price objective on the stock. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Agilent Technologies from $155.00 to $165.00 and gave the stock an “overweight” rating in a research note on Thursday, October 9th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $149.62.

Insiders Place Their Bets

In other news, CEO Padraig Mcdonnell sold 12,490 shares of the stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $150.00, for a total transaction of $1,873,500.00. Following the completion of the transaction, the chief executive officer directly owned 33,448 shares of the company’s stock, valued at $5,017,200. This represents a 27.19% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.26% of the stock is currently owned by insiders.

Agilent Technologies Stock Performance

Shares of Agilent Technologies stock opened at $146.90 on Friday. The business’s fifty day simple moving average is $137.63 and its 200 day simple moving average is $123.77. The company has a current ratio of 2.25, a quick ratio of 1.71 and a debt-to-equity ratio of 0.53. Agilent Technologies, Inc. has a 12 month low of $96.43 and a 12 month high of $153.84. The firm has a market capitalization of $41.65 billion, a P/E ratio of 34.48, a price-to-earnings-growth ratio of 4.67 and a beta of 1.29.

Agilent Technologies (NYSE:A) last announced its earnings results on Wednesday, August 27th. The medical research company reported $1.37 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.37. The firm had revenue of $1.74 billion during the quarter, compared to analyst estimates of $1.67 billion. Agilent Technologies had a return on equity of 25.51% and a net margin of 17.97%.The business’s revenue was up 10.1% compared to the same quarter last year. During the same period last year, the firm posted $1.32 EPS. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. As a group, analysts anticipate that Agilent Technologies, Inc. will post 5.58 EPS for the current year.

Agilent Technologies Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, October 22nd. Shareholders of record on Tuesday, September 30th were given a $0.248 dividend. The ex-dividend date of this dividend was Tuesday, September 30th. This represents a $0.99 annualized dividend and a yield of 0.7%. Agilent Technologies’s payout ratio is currently 23.24%.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.